Non-Coding RNAs and resistance to anticancer drugs in gastrointestinal tumors

68Citations
Citations of this article
51Readers
Mendeley users who have this article in their library.

Abstract

Non-coding RNAs are important regulators of gene expression and transcription. It is well established that impaired non-coding RNA expression especially the one of long non-coding RNAs and microRNAs is involved in a number of pathological conditions including cancer. Non-coding RNAs are responsible for the development of resistance to anticancer treatments as they regulate drug resistance-related genes, affect intracellular drug concentrations, induce alternative signaling pathways, alter drug efficiency via blocking cell cycle regulation, and DNA damage response. Furthermore, they can prevent therapeutic-induced cell death and promote epithelial-mesenchymal transition (EMT) and elicit non-cell autonomous mechanisms of resistance. In this review, we summarize the role of non-coding RNAs for different mechanisms resulting in drug resistance (e.g., drug transport, drug metabolism, cell cycle regulation, regulation of apoptotic pathways, cancer stem cells, and EMT) in the context of gastrointestinal cancers.

Cite

CITATION STYLE

APA

Hahne, J. C., & Valeri, N. (2018, June 18). Non-Coding RNAs and resistance to anticancer drugs in gastrointestinal tumors. Frontiers in Oncology. Frontiers Media S.A. https://doi.org/10.3389/fonc.2018.00226

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free